PROTOCOLOS CLÍNICOS E DIRETRIZES TERAPÊUTICAS

Doença Falciforme Doença Falciforme 13 R eferências Bibliográficas 1. Weatherall DJ, Clegg JB. Inherited haemoglobin disorders: a increasing global health problem. Bull World Health Organ. 2001;79(8):704-12. Epub 2001 Oct 24. 2. Weatherall D, Akimyanju O, Fucharoen S, Olivieri N, Musgrove P. Inherited disorders of hemoglobin. In: Jamison DT, Mosley WH, Measham AR, Bobadilla JL, editors. Disease control priorities in developing countries. 2nd Ed. Oxford: Oxford University Press; 2006. p. 663-80 . Available from: http://www.ncbi.nlm.nih . gov/bookshelf/picrender.fcgi?book=dcp2&part=A10761&blobtype=pdf. 3. Platt OS. The acute chest syndrome of sickle cell disease [editorial]. New England J Med. 2000;342(25): 1904-7. 4. Zago MA, Pinto ACS. Fisiopatologia das doenças falciformes: da mutação genética à insuficência de múltiplos órgãos. Rev Bras Hematol Hemoter. 2007;29(3):207-14. 5. Schechter AN. Hemoglobin research and the origins of molecular medicine. Blood. 2008;112(10):3927-38. 6. Parra FC, Amado RC, Lambertucci JR, Rocha J, Antunes CM, Pena SD. Color and genomic ancestry in Brazilians. Proc Natl Acad Sci U S A. 2003;100(1):177-82. Epub 2002 Dec 30. 7. Cançado RD, Jesus JA. A doença falciforme no Brasil. Rev Bras Hematol Hemoter. 2007;29(3):204-6. 8. de Paiva e Silva RB, Ramalho AS, Cassorla RMS. A anemia falciforme como problema de Saúde Pública no Brasil. Rev Saude Publica. 1993;27(1):54-8. 9. Silla LMR. Doença falciforme: um grave e desconhecido problema de saúde pública no Brasil. J Pediatr (Rio J). 1999;75(3):145-6. 10. Guedes C, Diniz D. Um caso de discriminação genética: o traço falciforme no Brasil. Physis [online]. 2007;17(3):501-20. 11. Ministério da Saúde, Brasil. Portaria nº 1.391/GM de 16 de agosto de 2005. Brasília: Ministério da Saúde; 2005 [citado 20 Ago 2009]. Disponível em: http://dtr2001.saude.gov.br/sas/PORTARIAS/Port2005/GM/GM- 1391.htm. 12. Gladwin MR, Vichinsky E. Pulmonary complications of sickle cell disease. N Engl J Med. 2008;359(21): 2254-65. 13. Wood KC, Granger DN. Sickle cell disease: role of reactive oxygen and nitrogen metabolites. Clin Exp Pharmacol Physiol. 2007;34(9):926-32. 14. Hebbel RP, Osarogiagbon R, Kaul D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation. 2004;11(2):129-51. 15. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev. 2007;21(1):37-47. Epub 2006 Nov 7. 16. Vichinsky E, Hurst D, Earles A, Kleman K, Lubin B. Newborn screening for sickle cell disease: effect on mortality. Pediatrics. 1988;81(6):749-55. 17. Strouse JJ, Lanzkron S, Beach MC, Haywood C, Park H Witkop C, et al. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. Pediatrics. 2008;122(6):1332-42. 18. Agência Nacional de Vigilância Sanitária (ANVISA). Manual de diagnóstico e tratamento de doenças falciformes. Brasília: Ministério da Saúde; 2002 [citado 11 Mai 2010]. Disponível em: http://bvsms.saude.gov . br/bvs/publicacoes/anvisa/diagnostico.pdf. 19. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330(23):1639-44. 20. Hankins JS, Ware RE, Rogers ZR, Wynn LW, Lane PA, Scott JP, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood. 2005;106(7):2269-75. 21. Thompson BW, Miller ST, Rogers ZR, Rees RC, Ware RE, Waclawiw MA, et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatr Blood Cancer. 2010;54(2):250-5. 22. Steinberg MH, Barton F, Castro O, Pegelow CH, Balas SK, Kutlar A, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289(13): 1645-51. 23. Charache S, Terrin ML, Moore RD, Dover GJ Barton FB, Eckert SV, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332(20):1317-22 24. Platt OS. Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med. 2008;358(13):1362-9. 239